Visium Asset Management’s Stemline Therapeutics STML Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q4
– Sell
-150,000
Closed -$1.87M – 1252
2014
Q3
$1.87M Hold
150,000
– – 0.03% 481
2014
Q2
$2.2M Hold
150,000
– – 0.03% 391
2014
Q1
$3.05M Hold
150,000
– – 0.05% 310
2013
Q4
$2.94M Hold
150,000
– – 0.06% 278
2013
Q3
$6.79M Sell
150,000
-150,000
-50% -$4.89M 0.15% 110
2013
Q2
$7.15M Buy
+300,000
New +$4.78M 0.17% 95

Other funds holding STML

Visium Asset Management's STML Position: Q4 2014 in Review

Visium Asset Management sold out of Stemline Therapeutics (STML) in Q4 2014, closing a stake of 150,000 shares — an estimated $1.87M sold.

Visium Asset Management first reported a position in STML in Q2 2013 and held it in 6 quarters. The position peaked at $7.15M in Q2 2013. 62 funds tracked by Wall St. Rank hold STML as of Q4 2014.

  • Visium Asset Management reported no remaining Stemline Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Visium Asset Management sold 150,000 Stemline Therapeutics shares in Q4 2014, an estimated $1.87M.
  • Visium Asset Management first reported a position in Stemline Therapeutics in Q2 2013 and held it in 6 quarters.
  • Visium Asset Management's Stemline Therapeutics position peaked at $7.15M in Q2 2013.
  • 62 funds tracked by Wall St. Rank held Stemline Therapeutics as of Q4 2014.

Based on Visium Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.